FWM
TVRD

Filbrandt Wealth Management’s Tvardi Therapeutics TVRD Stock Holding History

Filbrandt Wealth Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3
Closed -$2K – 367
2020
Q2 		$2K Sell
3
-1
-25% -$552 ﹤0.01% 330
2020
Q1 		$2K Buy
+4
New +$2.17K ﹤0.01% 190

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Filbrandt Wealth Management's TVRD Position: Q3 2020 in Review

Filbrandt Wealth Management sold out of Tvardi Therapeutics (TVRD) in Q3 2020, closing a stake of 3 shares — an estimated $2K sold.

Filbrandt Wealth Management first reported a position in TVRD in Q1 2020 and held it in 2 quarters. The position peaked at $2K in Q2 2020. 161 funds tracked by Wall St. Rank hold TVRD as of Q3 2020.

  • Filbrandt Wealth Management reported no remaining Tvardi Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Filbrandt Wealth Management sold 3 Tvardi Therapeutics shares in Q3 2020, an estimated $2K.
  • Filbrandt Wealth Management first reported a position in Tvardi Therapeutics in Q1 2020 and held it in 2 quarters.
  • Filbrandt Wealth Management's Tvardi Therapeutics position peaked at $2K in Q2 2020.
  • 161 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2020.

Based on Filbrandt Wealth Management's 13F filing for Q3 2020, filed 29 Oct 2020.